O14

Urothelial bladder cancer risk patterns according to tumor taxonomic subtypes

By: Benítez Dorta R. 1, Pineda S. 2, Domínguez S. 2, Rava M. 2, Sirab N. 3, Tardón A. 4, Carrato A. 5, Serra C. 6, García-Closas R. 7, Rothman N. 8, Silverman D. 8, Kogevinas M. 9, Allory Y. 9, X Real F. 2, Malats N. 2

1Spanish National Cancer Research Center (CNIO) and CIBERONC, Genetic and Molecular Epidemiology Group, Madrid, Spain, 2Spanish National Cancer Research Center (CNIO), Genetic and Molecular Epidemiology Group, Madrid, Spain, 3Institut Curie, Pathological Department, Saint Cloud, France, 4IUOPA and CIBERESP, Universidad de Oviedo, Oviedo, Spain, 5Ramón y Cajal University Hospital and CIBERONC, Medical Oncology Service, Madrid, Spain, 6Consorti Hospitalari Parc Taulí, Consorci Hospitalari Parc Taulí, Sabadell, Spain, 7Hospital Universitario de Canarias, Unidad de Investigación, La Laguna, Tenerife, Spain, 8National Cancer Institute, Department of Health and Human Services, Bethesda, United States of America, 9Hospital del Mar Medical Research Institute and CIBERESP, IMIM, Barcelona, Spain

O15

Immune infiltrate, immune checkpoints and mismatch repair proteins in testicular germ cell tumors: A role in prognosis and patient outcome

By: Lobo J. 1, Rodrigues A.R. 1, Guimarães R.G. 1, Cantante M.C. 1, Lopes P.L. 1, Maurício J. 2, Oliveira J. 3, Jerónimo C.J. 4, Henrique R.H. 1

1Portuguese Oncology Institute of Porto (IPOP), Dept. of Pathology, Porto, Portugal, 2Portuguese Oncology Institute of Porto (IPOP), Dept. of Medical Oncology & Urology Clinic, Porto, Portugal, 3Portuguese Oncology Institute of Porto (IPOP), Dept. of Urology & Urology Clinic, Porto, Portugal, 4Portuguese Oncology Institute of Porto (IPOP), Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Porto, Portugal

O16

Immunogenomic analysis reveals that tumor aggressiveness is associated with a decreased CD8 T cell signature in an in vivo prostate cancer model

By: van Gelder M.A. 1, Marques R. 1, De Ridder C.M.A. 1, Stuurman D.S. 1, Berrevoets C. 2, Debets J.E.M.A. 2, Van Weerden W.M. 1

1Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus University Medical Center, Dept. of Medical Oncology, Rotterdam, The Netherlands
The mTOR kinase directly regulates FBP1 gene expression via interaction with SWI/SNF chromatin remodeling complex in clear cell renal cell carcinoma (ccRCC).


1Cancer Center and Institute of Oncology, Department of Molecular and Translational Oncology, Warsaw, Poland, 2Institute of Biochemistry and Biophysics Polish Academy of Sciences, Department of Protein Biosynthesis, Warsaw, Poland, 3Cancer Center and Institute of Oncology, Department of Uro-oncology, Warsaw, Poland, 4Cancer Center and Institute of Oncology, Department of Pathology, Warsaw, Poland